Indivior Pharmaceuticals (INDV) Invested Capital (2021 - 2025)
Indivior Pharmaceuticals has reported Invested Capital over the past 5 years, most recently at -$69.0 million for Q4 2025.
- Quarterly results put Invested Capital at -$69.0 million for Q4 2025, down 1625.0% from a year ago — trailing twelve months through Dec 2025 was -$69.0 million (down 1625.0% YoY), and the annual figure for FY2025 was -$69.0 million, down 1625.0%.
- Invested Capital for Q4 2025 was -$69.0 million at Indivior Pharmaceuticals, up from -$189.0 million in the prior quarter.
- Over the last five years, Invested Capital for INDV hit a ceiling of $437.0 million in Q4 2021 and a floor of -$310.0 million in Q3 2024.
- Median Invested Capital over the past 5 years was -$161.0 million (2024), compared with a mean of -$65.3 million.
- Peak annual rise in Invested Capital hit 39.03% in 2025, while the deepest fall reached 1625.0% in 2025.
- Indivior Pharmaceuticals' Invested Capital stood at $437.0 million in 2021, then dropped by 29.29% to $309.0 million in 2022, then plummeted by 81.88% to $56.0 million in 2023, then tumbled by 107.14% to -$4.0 million in 2024, then plummeted by 1625.0% to -$69.0 million in 2025.
- The last three reported values for Invested Capital were -$69.0 million (Q4 2025), -$189.0 million (Q3 2025), and -$239.0 million (Q2 2025) per Business Quant data.